1. 恶性肿瘤（胃肠肿瘤）的内科治疗2. 晚期肿瘤分子靶向治疗及免疫治疗3. 新药I期临床研究
国家级学会任职：
中国临床肿瘤学会（CSCO）基金会理事长President of Chinese Society of Clinical Oncology(CSCO) Foundation
中国临床肿瘤学会（CSCO）前理事长President of Chinese Society of Clinical Oncology(CSCO)
亚洲肿瘤学联盟（FACO)主席President of Federation of Asian Clinical Oncology (FACO)
亚洲肿瘤分子靶向治疗继续教育委员会（MTTC）常委Standing committee member of Medical Education Workshop on Molecular Targeted Therapy of Cancer (MTTC)
中国医师学会结直肠癌专业委员会副主任委员Vice chairman of Chinese medical doctor association colorectal cancer group
中国临床肿瘤学会药物安全专家委员会主任委员Chairman of Anti-cancer drug Safety Management Committee (ASMC)
上海市抗癌协会胃肠肿瘤专业委员会副主任委员Vice chairman of Shanghai Anti-cancer Association GI group
学术杂志编委：《Cancer Science》， 副主编Associate editor of Cancer Science
《Journal of Colorectal Cancer》中文版 ， 副主编Associate editor of Journal of Colorectal Cancer(Chinese version)
《中华肿瘤杂志》 编委Editor of Chinese Journal of Oncology
《癌症》 责任编委Editor of Cancer
《中国癌症杂志》 编委Editor of China Oncology
《临床肿瘤学杂志》 副主编Associate editor of Chinese Clinical Oncology
《Journal of Colorectal Cancer》中文版 副主编Associate editor of Journal of Colorectal Cancer (Chinese version)
《Journal of Hematology and Oncology》 编委Editor of Journal of Hematology and Oncology
《Clinical Cancer Drugs》 编委Editor of Clinical Cancer Drugs
主持科研项目：
1. 肿瘤新药I期临床研究的标准化和智能化研究及应用示范（19431908200）🧜🏼♂️；项目来源：上海市科学技术委员会🏌🏼⛓️💥；起止年月：2019.12 -2022.11.30；资助金额：100万🫵🏼；
2019.12 -2022.11.30 Title: Standardized and intellectualized research and application of phase I clinical trials of novel anti-cancer drugs
Grant NO.: 19431908200 (¥1,000,000)
Major goal: to establish the standard and intellectualized platform for phase I clinical trials of anti-cancer drugs
2. 科技部非传染性疾病防控研究（2017YFC1308902），胃癌靶向治疗新技术研究-靶向药物治疗胃癌的早期临床研究及多中心大样本临床研究；项目来源🏂🏼：中华人民共和国科技部；起止年月：2017.07-2020.12🧒🏽；资助金额🧞：770万；
2017.07-2020.12 Title: targeted treatment for gastric cancer: early clinical trial and multi-center clinical trial
Grant NO.: 2017YFC1308902 (¥7,700,000)
Major goal: to find new effective target for gastric cancer treament and investigate new drug for gastric cancer.
3. 复发转移大肠癌的治疗新策略（2016ZX-07-003）；项目来源：国家卫生计生委医药卫生科技发展研究中心；起止年月：2016.11-2018.12；资助金额：1000万📥🏊🏼♂️；
2016.11-2018.12 Title: new strategy for metastatic colorectal cancer
Grant NO.: 2016ZX-07-003 (¥10,000,000)
Major goal: to find new strategies for mCRC, especially targeted therapy and immunotherapy.
4. 基于外显子测序技术筛选胃癌复发转移新基因CDH4突变及其功能研究👨🏿🚒；项目来源👩🏽🔧：国家自然科学基金；起止年月：2018.01-2020.12；资助金额：55万；
2018.01-2020.12 Title: role of CDH4 mutation in grastric cancer recurrence based on whole exome sequence
Grant NO.: 2016ZX-07-003 (¥10,000,000)
Major goal: to investigate the role of CDH4 mutation in gastric cancer recurrence, and possible mechanism.
5. 国际标准抗肿瘤新药临床试验平台建设（2012ZX09303-018-002）；项目来源🤸♀️：国家十二五重大攻关计划课题🧑🏻🚀👩🏼🎓；起止年月💇🏼♂️：2012.01-2017.12；资助金额：1400万。
2012.01-2017.12 Title: establishment of international standardized new platform for anti-cancer drug clinical trial.
Grant NO.: 2012ZX09303-018-002 (¥14,000,000)
Major goal: to establish new platform for new drug clinical trial.
获奖成果：
1. 2014年“胃癌发生发展的分子机制研究与临床治疗新策略的建立和应用《国家教育部科技进步》二等奖👱🏻。（排名第1）
2014 Ministry of Education Prize for Progress in Science and Technology, second award (No. 1).
2. 2016年结直肠癌个体化治疗策略创新与应用《国家科技进步奖》二等奖 (排名第3)
2016 National Prize for Progress in Science and Technology, second award (No. 3).
主要论著(第一作者或通讯作者）🖐🏽：
[1] Duan, X., X. Xu, Y. Zhang, Y. Gao, J. Zhou, and J. Li, DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18. Cancer Sci, 2022.
[2] Xu, X., X. Duan, S. Wang, Y. Zhang, Y. Gao, X. Xu, G. Yeerkenbieke, J. Zhou, and J. Li, Special issue "The advance of solid tumor research in China": Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating AKT signaling. Int J Cancer, 2022.
[3] Qin, S., J. Li, et al. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. BioDrugs, 2021. 35(4): p. 445-458.
[4] Li, J., et al, Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Adv Ther, 2020. 37(11): p. 4585-4598.
[5] Li J, Qin SK, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496.
[6] Xu, JM, … , Li, J; Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study , Journal of Clinical Oncology, 2018, 36(4): 350-358.
[7] Qin, SK; Li, J; et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial , Journal of Clinical Oncology, 2018, 36(30): 3031-3039.
[8] Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev. 2018 Jan;38(1):325-376.
[9] Liu x, Zhang X, Li J, et al. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. Int J Cancer. 2017 Nov 15;141(10):2093-2102.
[10] Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017 Jan 19;10(1):22.
